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Aims We investigated the role of src-family kinases (srcFKs) in hypoxic pulmonary vasoconstriction (HPV)
and how this relates to Rho-kinase-mediated Ca
2þ sensitization and changes in intracellular Ca
2þ con-
centration ([Ca
2þ]i).
Methods and results Intra-pulmonary arteries (IPAs) were obtained from male Wistar rats. HPV was
induced in myograph-mounted IPAs. Auto-phosphorylation of srcFKs and phosphorylation of the regul-
atory subunit of myosin phosphatase (MYPT-1) and myosin light-chain (MLC20) in response to hypoxia
were determined by western blotting. Translocation of Rho-kinase and effects of siRNA knockdown of
src and fyn were examined in cultured pulmonary artery smooth muscle cells (PASMCs). [Ca
2þ]i was esti-
mated in Fura-PE3-loaded IPA. HPV was inhibited by two blockers of srcFKs, SU6656 and PP2. Hypoxia
enhanced phosphorylation of three srcFK proteins at Tyr-416 (60, 59, and 54 kDa, corresponding to
src, fyn, and yes, respectively) and enhanced srcFK-dependent tyrosine phosphorylation of multiple
target proteins. Hypoxia caused a complex, time-dependent enhancement of MYPT-1 and MLC20 phos-
phorylation, both in the absence and presence of pre-constriction. The sustained component of this
enhancement was blocked by SU6656 and the Rho-kinase inhibitor Y27632. In PASMCs, hypoxia caused
translocation of Rho-kinase from the nucleus to the cytoplasm, and this was prevented by anti-src
siRNA and to a lesser extent by anti-fyn siRNA. The biphasic increases in [Ca
2þ]i that accompany HPV
were also inhibited by PP2.
Conclusion Hypoxia activates srcFKs and triggers protein tyrosine phosphorylation in IPA. Hypoxia-
mediated Rho-kinase activation, Ca
2þ sensitization, and [Ca
2þ]i responses are depressed by srcFK
inhibitors and/or siRNA knockdown, suggesting a central role of srcFKs in HPV.
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1. Introduction
Hypoxic pulmonary vasoconstriction (HPV) is the acute loca-
lized adaptive process whereby blood ﬂow is directed away
from poorly ventilated areas of the lung in order to maxi-
mize ventilation–perfusion matching. In isolated pulmonary
arteries, HPV is typically biphasic, characterized by a large
but transient ﬁrst phase and a sustained and often gradually
developing second phase.
1,2 The ﬁrst phase is associated
with a sizeable transient elevation in intracellular Ca
2þ
([Ca
2þ]i), whereas during the second phase, there is a
relatively small and rapidly stabilizing increase in [Ca
2þ]i,
2 the effect of which is greatly enhanced by a Rho-kinase-
dependent Ca
2þ sensitization pathway.
3
src-family kinases (srcFKs) are a group of closely related
non-receptor tyrosine kinases, of which three (src, fyn,
and yes) are highly expressed in pulmonary artery.
4 Although
tyrosine kinases are essential components of cell growth and
proliferation signalling, they have also been implicated in
vascular smooth muscle contraction.
5,6 We have recently
shown in rat pulmonary artery, as have others in porcine
coronary artery, that agonist-induced Rho-kinase-mediated
Ca
2þ sensitization and force generation is dependent on
srcFKs.
4,7
Ca
2þ sensitization of the contractile apparatus occurs
through inhibition of myosin light-chain phosphatase
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doi:10.1093/cvr/cvn209(MLCP), leading to increased phosphorylation of the 20 kDa
myosin light-chain (MLC20), independently of changes in
[Ca
2þ]i.
8 MLCP inhibition occurs through phosphorylation of
the myosin-binding subunit MYPT-1
9 via Rho-kinase.
10,11 We
have shown that the second phase of HPV is selectively
inhibited by the Rho-kinase blocker Y27632 but not by the
PKC blocker Ro31-8220.
2,3 In addition, hypoxia enhances
phosphorylation of MYPT-1 and MLC20 in cultured pulmonary
artery smooth muscle cells (PASMCs).
12,13 Rho-kinase-
mediated Ca
2þ sensitization is also a key factor in the patho-
genesis of chronic hypoxia-induced pulmonary
hypertension.
14,15
Two studies using broad-spectrum tyrosine kinase blockers
(genistein and tyrphostin) have suggested the involvement
of tyrosine kinases in HPV.
16,17 src and fyn are both activated
by hypoxia in cardiac myocytes,
18 and src plays a crucial role
in hypoxia-inducible factor (HIF-1) induction in vascular
smooth muscle cells.
19 However, a speciﬁc role of srcFKs in
HPV and the contractile pathways affected remains to be
determined. In the present study, therefore, we evaluated
the role of srcFKs in HPV of rat small distal pulmonary
arteries and determined how this relates to the hypoxia-
mediated Rho-kinase-dependent Ca
2þ sensitization and
[Ca
2þ]i responses.
2. Methods
2.1 Animals, solutions, drugs, and chemicals
This study conforms with the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996). Male Wistar rats (200–250 g)
were killed by lethal overdose of pentobarbital (ip), with approval
from local Ethics Review Board. Lungs were excised, then ﬁrst- to
third-order branches of the intra-pulmonary artery (IPA) were dis-
sected free of surrounding parenchyma and placed in physiological
salt solution (PSS), containing in mM: NaCl 118; NaHCO3 24; KCl 4;
CaCl2 1.8; MgSO4 1; NaH2PO4 0.43; and glucose 5.56. A normal pH
of 7.4 was maintained by gassing samples with air containing 5%
CO2. For hypoxia, gassing in different test chambers was adjusted
in each case to achieve a pO2 of 15 Torr. SU6656, PP2, PP3, and
Y27632 were all obtained from Calbiochem (Merck Biosciences
Nottingham, UK). Fura-PE3/AM was purchased from Sigma (Poole,
UK). PGF2a (tromethamine salt) was purchased from Biomol (Exeter,
UK). All other reagents were obtained from Calbiochem, Sigma,
Invitrogen (Paisley, UK), or Fisher (Loughborough, UK).
2.2 Measurement of force and intracellular Ca
21
Intra-pulmonary arteries (second- to third-order; 150–400 mm dia-
meter) were mounted on a Mulvany–Halpern wire myograph (DMT
A/S, Aarhus, Denmark), bathed in PSS at 378C, pH 7.4, and stretched
to give a wall tension equivalent to a transmural pressure of
30 mmHg.
1 All tension experiments were preceded by equilibration
with three 3 min contractions to 80 mM K
þ-substituted PSS (K
þPSS).
In order to elicit a full contractile response to hypoxia, IPAs were
pre-constricted with a concentration of PGF2a necessary to
produce tension equivalent to 10–15% of that produced by 80 mM
K
þPSS (typically 5 mM), and then made hypoxic for 40 min. Two
HPV responses were elicited in each artery; the second of which
in treated arteries was preceded by a 10 min pre-incubation with
inhibitor. In the presence of inhibitor, the concentration of PGF2a
required to achieve a 10–15% pre-constriction was adjusted
accordingly.
20
Isolated IPAs were mounted either on a modiﬁed Cambustion
AM-10 myograph (Cambustion Ltd, Cambridge, UK) or on a confocal
wire myograph (Danish Myo Technology). After stretching and
equilibration as described above, IPAs were incubated for 1 h at
378C in PSS containing 4 mM Fura PE-3/AM, and for a further
30 min to allow for de-esteriﬁcation. Myograph modules were
mounted on an inverted microscope (Nikon Diaphot, Nikon UK Ltd,
Kingston-upon-Thames, UK) with a  10 or  20 Fluor objective
combined with a double-excitation microﬂuorimeter (CairnResearch
Ltd, Faversham, UK). Tension was recorded simultaneously with
light emitted by the whole artery at .510 nm at excitation wave-
lengths 340 and 380 nm. The ratio of the emission intensities
(R340/380) was taken as a measure of [Ca
2þ]i.
2.3 Western blot
Intra-pulmonary artery samples (half main IPA plus 2–3 second-order
side-branches per sample) were subjected to a 15 min equilibration
period in normoxic PSS at 378C, followed by a 10 min pre-incubation
with pharmacological agents where appropriate. IPAs were then
made hypoxic for 1, 2 5, 10, or 30 min and snap frozen in liquid
N2, prior to homogenization. Protein was extracted in 50 mLo f
Tris–SDS sample buffer containing phosphatase and protease inhibi-
tor cocktails (Sigma). Protein extracts (12–15 mL per lane) were run
on SDS–PAGE gels (4–12% gradient, Invitrogen), transferred to nitro-
cellulose membrane and blocked with 5% skimmed milk for 1 h at
room temperature. Membranes were probed with primary antibody
overnight at 48C (1:500–1:5000 dilution where appropriate) in Tris-
buffered saline containing 0.05% Tween 20 and 1% skimmed milk,
followed by horseradish-peroxidase-conjugated anti-IgG secondary
antibody for 1 h at room temperature (1:5000 dilution with 1%
milk). Protein bands were visualized with chemiluminescence
reagent (Pierce, Cramlington, UK, or Amersham, Bucks., UK) and
then exposed to photographic ﬁlm. Membranes were ﬁrst probed
with anti-phospho-antibodies, stripped for 1 h (Pierce stripping
buffer), re-blocked, and re-probed with corresponding anti-total
antibodies. Band intensity was expressed as a ratio of phospho/
total for each protein, and values from each treated sample were
normalized to those from control (untreated) samples run on the
same gel. Two to three control samples were run on each gel and
averaged. Antibodies were obtained from Cell Signalling, Upstate
(UK), Santa Cruz Biotechnology (CA, USA), or Sigma.
2.4 siRNA design and transfection
siRNAs were designed as described previously.
21,22 The 19 nucleotide
target sequences (src-siRNA: position 614–632, GenBank accession
no. AF157016; and fyn-siRNA: position 1096–1114, GenBank acces-
sion no. U35365) were synthesized into 64–65 mer oligonucleotides
with BamHI/HindIII overhangs (Euroﬁns MWG Operon) and cloned
into the expression vector pSilencer 3.0-H1 (Ambion Inc.). All
clones were puriﬁed using an EndoFree Plasmid Maxi Kit (Qiagen
Ltd) and sequenced (Geneservice Ltd) (see Supplementary material
online for more details).
Pulmonary artery smooth muscle cells were dispersed enzymati-
cally and grown in DMEM with 10% FCS to passage 3 or 4. Cells
were plated on 13 mm coverslips and then growth arrested for
24 h. Identiﬁcation of cells as smooth muscle was veriﬁed by posi-
tive staining with anti-smooth muscle a-actin and anti-calponin
antibodies (as described previously
4). Cells were transfected using
the Basic Nucleofector
w Kit for primary smooth muscle cells and a
nucleofector device (Amaxa Biosystems). After 72 h, the transfec-
tion efﬁciency was .90%, determined using pmaxGFP (green ﬂuor-
escent protein expressing vector) provided in the kit and conﬁrmed
by ﬂuorescence microscopy. Efﬁciency and selectivity of knockdown
was conﬁrmed by western blot (see Supplementary material online).
2.5 Rho-kinase translocation
Pulmonary artery smooth muscle cells were treated in DMEM at 378C
under either normoxic or hypoxic conditions for 40 min. Reactions
were terminated by addition of paraformaldehyde ﬁxative. Fixed
cells were permeabilized with Triton-100 and stained overnight
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incubation with Alexa Fluor 488-labelled secondary antibody
(1:300) for 2 h at room temperature. Speciﬁcity of anti-ROCK-2
was conﬁrmed by western blot (single band at 160 kDa), and staining
was negative with secondary antibody alone (as described
previously
4).
2.6 Data analysis and statistics
Western blot images were quantiﬁed by ImageJ software (rsb.info.
nih.gov). Stained cells were photographed and analysed with
Zeiss Axiovert-200 microscope with CARV II confocal imager
(BD Biosciences) and MetaMorph software (Molecular Devices).
Statistical analysis was performed with SigmaStat (Systat Software
Inc., San Jose, CA, USA). Time-dependent effects of hypoxia on
tension or [Ca
2þ]i or of hypoxia and/or PGF2a on phosphorylation
were examined by two-way repeated measures ANOVA with appro-
priate post hoc tests. Comparisons of the effects of different
drugs against hypoxia or PGF2a were performed by one-way ANOVA
with Holm–Sidak post hoc tests or by Kruskal–Wallis one-way
ANOVA on ranks, where appropriate.
3. Results
3.1 srcFK inhibitors block hypoxic
pulmonary vasoconstriction
Hypoxic pulmonary vasoconstriction was induced by pre-
constricting IPA with a low concentration of PGF2a (typically
5–10 mM) then making the chamber hypoxic for 40 min.
Hypoxia induced a biphasic contractile response comprising
a rapid transient phase followed by a slower sustained
phase which was fully reversed upon re-oxygenation,
as described previously.
1–3 Two hypoxic exposures were per-
formed in each artery. Drugs were applied during the
second exposure and their effects were compared with the
second exposure in untreated time controls. In time control
experiments, the second HPV response was consistently
larger than the ﬁrst (n ¼ 16, data not shown). HPV was inhib-
ited by pre-incubation with the srcFK inhibitors SU6656
23 and
PP2
24,25 (Figure 1A and B). We used concentrations of SU6656
and PP2 previously shown to be required for inhibition of
srcFK auto-phosphorylation and protein tyrosine phosphoryl-
ation in IPAs.
4 The sustained phase was diminished by both
Figure 1 Effects of src-family kinase (srcFK) inhibitors on hypoxic pulmonary vasoconstriction in intra-pulmonary arteries. Intra-pulmonary arteries were pre-
constricted with PGF2a before being made hypoxic. Example traces (top panels) show the effects of hypoxia ﬁrst in the absence (upper trace), and then in the
presence (lower trace) of inhibitors. The sustained phase contraction was inhibited by the srcFK inhibitors SU6656 [(A)3mM, 33+10% block, *P , 0.05, n ¼ 8
arteries; 30 mM, 56+6% block, **P , 0.001, n ¼ 8 arteries] and PP2 [(B)3mM, 37+6% block, *P , 0.01, n ¼ 10 arteries; 30 mM, 64+9% block, **P , 0.001, n ¼
10 arteries]. The inactive analogue PP3 also partially inhibited the sustained phase at 30 mM[ ( C)2 8+6% block, *P , 0.05, n ¼ 8 arteries], but this effect was
signiﬁcantly less than for PP2 (
†P , 0.01 vs. 30 mM PP2); PP3 had no effect at 3 mM. The transient phase was partially inhibited by SU6656 (30 mM, 23+10% block,
*P , 0.01) and PP2 (30 mM, 35+9% block, *P , 0.01).
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only partially blocked by 30 mM. PP3, the inactive analogue
of PP2, had no effect at 3 mM and caused only a slight inhi-
bition of the sustained phase at 30 mM( Figure 1C).
3.2 Hypoxia enhances srcFK auto-phosphorylation
and PP2-sensitive protein tyrosine phosphorylation
To determine whether srcFKs were activated by hypoxia or
whether the effects of inhibitors reﬂected suppressed consti-
tutive activity, we ﬁrst examined srcFK auto-phosphorylation
(an indication of srcFK activation
26) and protein-tyrosine
phosphorylation in response to hypoxia in IPAs. As shown
previously,
4 three protein bands were visualized with anti-
srcFK antibodies: a doublet at 59/60 kDa and another at
54 kDa, corresponding to the src-family members src, fyn,
and yes, respectively. Figure 2A shows that hypoxia caused
a signiﬁcant and transient increase in srcFK (tyr-416) phos-
phorylation at the 59/60 kDa band (upper panel) and 54 kDa
band (lower panel). Several protein bands or collections of
bands were visualized with anti-phospho-tyrosine in IPAs.
Four of these, at 120, 95, 75, and 65 kDa are shown
in Figure 2B. Hypoxia enhanced immunoreactivity at three
of these bands, and this enhancement was reversed by prior
incubation with 30 mM PP2 or 30 mM SU6656.
3.3 Hypoxia enhances MYPT-1 and MLC20
phosphorylation
Since a small degree of pre-constriction is required for a full
HPV response, we evaluated the effects of hypoxia on
MYPT-1 and MLC20 phosphorylation in IPAs both in the pre-
sence and absence of PGF2a. Five micromolar PGF2a was
used throughout as this approximates the concentration
required to achieve the correct level of pre-constriction.
The effects of 5 mM PGF2a itself were also evaluated. Five
micromolar PGF2a alone caused a small but sustained
increase in phosphorylation at both sites (Figure 3A and B).
As is also shown in Figure 3A, hypoxia in the presence of
PGF2a caused a large sustained enhancement of MYPT-1
phosphorylation (at thr-855, equivalent to thr-850 in
human) that was substantially greater than that caused by
PGF2a alone. Hypoxia in the presence of PGF2a also caused
signiﬁcant enhancement of MLC20 phosphorylation (at
ser-19, target of myosin light-chain kinase) above that of
PGF2a alone. This response was biphasic, with a peak at
5 min and another increase towards 30 min (Figure 3B).
Figure 2 Effects of hypoxia on src-family kinase tyr-416 auto-phosphorylation and protein tyrosine phosphorylation in intra-pulmonary artery. (A) Hypoxia
enhanced phospho-src (tyr-416) immunoreactivity at 60 and 54 kDa in a time-dependent manner (*P , 0.05 vs. control, n ¼ 9–11 rats). (B) Hypoxia (30 min)
also enhanced phospho-tyrosine immunoreactivity at several protein bands (*P , 0.05, **P , 0.01 vs. control, n ¼ 20 rats). At 120, 95, and 75 kDa, this
enhancement was reversed by either PP2 or SU6656 (30 mM,
†P , 0.001 vs. hypoxia alone, n ¼ 8–11 rats). At 65 kDa, although not enhanced by hypoxia,
basal immunoreactivity was also greatly inhibited by both inhibitors (
#P , 0.0001 vs. control).
G.A. Knock et al. 456Figure 3 Effects of hypoxia and PGF2a on phosphorylation of MYPT-1 (120–130 kDa) and MLC20 (18 kDa) in intra-pulmonary artery. (A and B) Phosphorylation at
both sites was enhanced by 5 mM PGF2a (open circles, *P , 0.05 vs. control, n ¼ 12–13 rats). In the continued presence of 5 mM PGF2a, hypoxia caused substantial
further enhancement at both sites (ﬁlled circles,
†P , 0.05,
††P , 0.01 vs. PGF2a alone, n ¼ 12–17 rats). (C and D) In the absence of PGF2a, hypoxia caused a small
sustained increase in phosphorylation (*P , 0.05, **P , 0.01 vs. control, n ¼ 12–17 rats).
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both MYPT-1 and MLC20 phosphorylation. This was character-
ized by a reduction at 1 min, a small peak at 2 min, another
dip at 5–10 min, and a ﬁnal small increase towards 30 min,
which rose signiﬁcantly above control levels for both phos-
phorylation sites (Figure 3C and D).
3.4 srcFK and Rho-kinase inhibitors block
hypoxia-mediated MYPT-1 and MLC20
phosphorylation
In order to determine the contribution of Rho-kinase to
phosphorylation of MYPT-1 and MLC20 during hypoxia and
the possible upstream involvement of srcFK, we performed
additional 30 min exposures to hypoxia and 5 mM PGF2a,
both together and individually, with the addition of the
Rho-kinase inhibitor Y27632 and the srcFK blocker SU6656.
Both in the presence (Figure 4A) and absence (Figure 4B)
of PGF2a, the hypoxia-induced enhancement of phosphoryl-
ation at both sites was inhibited by both SU6656 and Y27632.
The small enhancement mediated by 5 mM PGF2a was inhib-
ited by Y27632 at both phosphorylation sites, but only the
phosphorylation of MYPT-1 was signiﬁcantly reduced by
SU6656 (Figure 4C). We have previously shown that basal
phosphorylation of MYPT-1 at thr-855 and of MLC20 at
ser-19 is unaffected by SU6656 but that basal MYPT-1 phos-
phorylation at thr-855 is almost abolished by Y27632.
4
Inhibition of MYPT-1 phosphorylation at thr-855 by SU6656,
therefore, suggests that srcFK may be regulating the activity
of Rho-kinase.
3.5 Hypoxia triggers srcFK-dependent
translocation of Rho-kinase in pulmonary
artery smooth muscle cells
I no r d e rt oc o n ﬁ r mt h a tsrcFKs were acting upstream of
Rho-kinase activation, we examined hypoxia-mediated trans-
location of Rho-kinase (ROCK-2) in PASMCs transfected with
siRNAs directed against src, fyn, and a combination thereof,
compared with sham-transfected cells. Basally, ROCK-2 was
localized to the nucleus, and this was unaffected by either
siRNA. Upon exposure to hypoxia, ROCK-2 translocated to
the cytosol and/or cytoskeleton (Figure 5A and D). In cells
transfected with src-siRNA and fyn-siRNA, however, translo-
cation was completely and partially prevented, respectively
(Figure 5B–D). Double transfection with both src- and fyn-
siRNAs also abolished translocation (Figure 5D).
Figure 4 Effects of inhibition of src-family kinase and Rho-kinase on MYPT-1 (120–130 kDa) and MLC20 (18 kDa) phosphorylation. (A) In the presence of PGF2a,
hypoxia greatly enhanced phosphorylation (**P , 0.001 vs. control, n ¼ 17 rats for both sites), and this enhancement was reversed by SU6656 (
†P , 0.01, n ¼ 10
rats for both sites) and Y27632 (
††P , 0.001, n ¼ 6 rats for both sites). (B) In the absence of PGF2a, a smaller but still signiﬁcant increase was apparent (*P , 0.01,
n ¼ 17 rats for both sites), and this increase too was inhibited by SU6656 (
†P , 0.01, n ¼ 10 rats for both sites) and Y27632 (
††P , 0.001, n ¼ 6 rats for both sites).
(C) Five micromolar PGF2a also enhanced phosphorylation (*P , 0.01, n ¼ 13 rats for both sites). This increase was signiﬁcantly reduced by both SU6656 [
†P ,
0.01 (MYPT-1 only), n ¼ 9 rats for both sites] and Y27632 (
††P , 0.001, n ¼ 6 rats for both sites).
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21]i response is PP2
sensitive
In addition to Ca
2þ sensitization pathways, a rise in [Ca
2þ]i is
almost certainly also essential for a full HPV response.
20 In
order to determine whether srcFKs are also involved in
changes in [Ca
2þ]i during hypoxia, we examined the
effects of the srcFK inhibitor PP2 in Fura-PE3-loaded IPA.
As shown in Figure 6, hypoxia induced a biphasic [Ca
2þ]i
response, comprising a large rapid transient phase followed
by a small sustained phase, superimposed on the smaller
PGF2a-mediated response. PP2 suppressed both the transi-
ent and sustained phases of this response. These experi-
ments were not repeated with the other srcFK blocker
SU6656 because of the overlap of this drug’s yellow colour
with the emission spectra of Fura-PE3.
4. Discussion
This study provides the ﬁrst direct evidence for a role or roles
of srcFKs in HPV and ﬁrm supportive evidence for the import-
ance of Ca
2þ sensitization in the sustained phase of the con-
traction. Our observations also forge a clear link between
the actions of Y27632 on hypoxic force generation
3,12 and
on hypoxia-mediated enhancement of Rho-kinase-dependent
MYPT-1 and MLC20 phosphorylation. Our ﬁndings that
hypoxia both activates srcFK and enhances PP2-sensitive tyro-
sine phosphorylation of multiple protein targets, coupled with
the inhibition of HPV by both SU6656 and PP2, are suggestive
of an active role of these kinases in HPV. Hypoxia has been
previously shown to activate src and the closely related
kinase fyn in cardiac myocytes,
18 and to enhance srcFK-
speciﬁc tyrosine phosphorylation and activation of focal
adhesion kinases p125
FAK and paxillin.
27,28 p125
FAK may be
the 120 kDa protein whose tyrosine phosphorylation was
enhanced by hypoxia and inhibited by PP2 in the present
study. HPV is believed to involve a change in the generation
of reactive oxygen species (ROS) in the mitochondria.
29,30
Many protein kinases, including srcFK, are activated by
ROS,
31,32 indeed src appears to play an essential role in
many of the intracellular pathways activated by hypoxia
and ROS in the systemic vasculature.
19 Exactly how srcFK
activity may be induced by ROS, assuming ROS production is
enhanced during hypoxia in IPAs, remains to be determined.
The time course of the phosphorylation responses to
hypoxia was complex. In the absence of PGF2a, hypoxia
caused a multi-phasic phosphorylation response ending in
sustained enhancement at the maximum time point of
30 min. The initial drop at 1 min was large enough to
become signiﬁcant with regards to MLC20 at ser-19. A
Figure 5 Hypoxia-mediated translocation of Rho-kinase in pulmonary artery smooth muscle cells: effects of src and fyn knockdown. (A–C) Examples of ROCK-2
staining in pulmonary artery smooth muscle cells either sham-transfected (A) or transfected with src-siRNA (B)o rfyn-siRNA (C), under either normoxic (left
panels) or hypoxic conditions (right panels). (D) Hypoxia-induced ROCK-2 translocation, as determined by the ratio of cytosol/nuclear staining intensity.
*P , 0.01 vs. normoxia;
†P , 0.01 vs. sham-transfected. n ¼ 4 experiments (in cells from four different rats).
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with MLC20 in the presence of PGF2a, and indeed, in isolated
IPAs, we sometimes observe a small very transient relaxation
immediately after inducing hypoxia that precedes the ﬁrst-
phase contraction (unpublished observations). The causes
of these ﬂuctuations are unknown. In the presence of
PGF2a, hypoxia caused a large sustained increase in
MYPT-1 phosphorylation. This, however, was not exactly mir-
rored by MLC20 phosphorylation, the time course of which
resembled the time course of contraction, with a distinct
transient ﬁrst phase at 5 min followed by a sustained
phase of up to 30 min. This is not surprising since the ﬁrst
phase of HPV is clearly associated with a large transient
increase in [Ca
2þ]i, whereas the sustained phase of HPV is
primarily associated with a Ca
2þ sensitization pathway, as
shown previously.
2,3,20
Prostanoids cause vascular smooth muscle contraction in
part via Rho-kinase-mediated phosphorylation of MYPT-1.
33
In addition, we have recently demonstrated a direct involve-
ment of srcFK in PGF2a-mediated Ca
2þ sensitization and
contraction in rat IPAs, in which we showed that srcFKs
were activated by PGF2a and provided evidence that
srcFKs were upstream mediators of Rho-kinase transloca-
tion, and phosphorylation of MYPT-1 and MLC20.
4 Similarly,
in this study, Rho-kinase-mediated MYPT-1 phosphorylation
was inhibited by SU6656, and hypoxia-induced translocation
of Rho-kinase in PASMCs was completely prevented by siRNA
knockdown of src and strongly inhibited by knockdown of
fyn. Therefore, srcFKs are clearly involved in the upstream
regulation of hypoxia-mediated Rho-kinase activity.
Since both hypoxia and PGF2a
4 activate srcFKs and enhance
MYPT-1 and MLC20 phosphorylation, we conﬁrmed that the
action of hypoxia on this phosphorylation or of srcFK block-
ers on HPV was independent of any action on the underlying
pre-constriction. Hypoxia caused enhancement of Rho-
kinase-mediated phosphorylation of MYPT-1 in the absence
as well in the presence of PGF2a, and this enhancement
was sensitive to an inhibitor of srcFKs (Figure 4B).
However, the relative effectiveness of hypoxia in the pre-
sence of PGF2a at enhancing phosphorylation (MYPT-1 at
30 min: 94%; and MLC20 at 30 min: 70%) was apparently
greater than the sum of the individual effects of hypoxia
alone and PGF2a alone (MYPT-1 at 30 min: 28 þ 29 ¼ 57%;
and MLC20 at 30 min: 21 þ 25 ¼ 46%), suggesting a synergis-
tic action of the two stimuli. This is mirrored by force gene-
ration, where hypoxia in the absence of pre-constriction
produced very small contractions of only 3–4% the size of
that caused by 80 mM K
þPSS,
1 and yet in the presence
of 5 mM PGF2a which produces contractions of 10–15% of
K
þPSS, hypoxia caused additional sustained contractions of
up to 30% of K
þPSS. Thus, stimulation of srcFKs by both
PGF2a and hypoxia may explain at least part of the enhance-
ment of HPV seen in the presence of this agonist.
In addition to an involvement in Ca
2þ sensitization, we
have also found that the srcFK inhibitor PP2 blocks the
hypoxia-mediated [Ca
2þ]i response in IPAs. It is well estab-
lished that the net phosphorylation status of MLC20 at
ser-19 involves a balance between Ca
2þ-calmodulin-
dependent phosphorylation by MLCK and constitutive de-
phosphorylation by MLCP.
8 Concomitant phosphorylation of
MYPT-1 by Rho-kinase together with even a small elevation
of [Ca
2þ]i will, therefore, greatly enhance the phosphoryl-
ation of MLC20. Inhibition of either MYPT-1 phosphorylation
or [Ca
2þ]i-mediated MLCK activation, or both will thus
inhibit force generation. In addition to triggering
Rho-kinase-mediated Ca
2þ sensitization, both hypoxia and
PGF2a cause an elevation of [Ca
2þ]i, which in both cases is
comprised of transient and sustained components.
20,34–36
In our hands, the transient component of the hypoxic
[Ca
2þ]i response is partly due to voltage-dependent Ca
2þ
inﬂux and partly due to capacitative Ca
2þ-inﬂux triggered
by release from thapsigargin-sensitive stores, whereas the
sustained component is probably due to inﬂux through
another as yet uncharacterized voltage-independent
pathway.
20 Other studies propound the importance of
inﬂux through voltage-gated Ca
2þ channels.
37,38 In any
case, srcFKs have been implicated in both voltage-
Figure 6 Effects of hypoxia and srcFKinhibition on [Ca
2þ]i in intra-pulmonary
arteries (IPAs). Example traces (upper panel) of the ratio of light emitted at
.510 nm from excitation at 340 nm over that at 380 nm (R340/380) against
time, and average effects with time (lower panel): 30 mM PP2 inhibited both
the ﬁrst phase (taken at 5 min; 58+6% block, *P , 0.01 vs. control, n ¼ 7
arteries) and the second phase (taken at 40 min; 43+7% block, *P , 0.01 vs.
control, n ¼ 7 arteries). Note: the level of [Ca
2þ]i immediately before IPAs
were made hypoxic was set to zero in order to distinguish the effect of PP2
on the underlying PGF2a-induced response from that of hypoxia per se.
G.A. Knock et al. 460dependent and -independent mechanisms of Ca
2þ mobiliz-
ation as triggered by either agonists or ROS.
39,40
In summary, our results suggest a direct role of srcFKs in
the acute contractile response to hypoxia in small pulmon-
ary arteries of rat. Since srcFK inhibitors block both hypoxia-
mediated Rho-kinase-dependent MYPT-1 phosphorylation
and the hypoxic [Ca
2þ]i response in IPAs, we may speculate
that srcFKs may act upstream of both key pathways to
MLC20 phosphorylation and contraction. The speciﬁc phos-
phorylation targets of srcFKs as activated by hypoxia,
whether they be guanine exchange factors
41 or guanine dis-
sociation inhibitors
42 leading to RhoA/Rho-kinase activation,
or L-type Ca
2þ channels
40 or phospholipase-Cg,
43 resulting in
[Ca
2þ]i mobilization, remain to be determined.
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Supplementary material is available at Cardiovascular
Research online.
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